Immunovia AB Statistics
Immunovia AB (1YR) Stock Statistics & Valuation Metrics
Total Valuation
Immunovia AB has a market cap or net worth of EUR 7.91M. The enterprise value is EUR 45.87M.
- Market Cap
- EUR 7.91M
- Enterprise Value
- EUR 45.87M
Share Statistics
Immunovia AB has 2,786,763,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 2,786,763,000
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
Immunovia AB’s return on equity (ROE) is -2.25 and return on invested capital (ROIC) is -108.35%.
- Return on Equity (ROE)
- -2.25
- Return on Assets (ROA)
- -1.65
- Return on Invested Capital (ROIC)
- -108.35%
- Return on Capital Employed (ROCE)
- -1.10
- Revenue Per Employee
- 38.06K
- Profits Per Employee
- -8.11M
- Employee Count
- 18
- Asset Turnover
- 0.01
- Inventory Turnover
- 673.86
Valuation Ratios
The current PE Ratio of Immunovia AB is -0.26. Immunovia AB’s PEG ratio is -0.00.
- PE Ratio
- -0.26
- PS Ratio
- 9.33
- PB Ratio
- 3.11
- Price to FCF
- -0.24
- Price to Operating Cash Flow
- -0.27
- PEG Ratio
- -0.00
Income Statement
In the last 12 months, Immunovia AB had revenue of 685.00K and earned -145.91M in profits. Earnings per share was -0.42.
- Revenue
- 685.00K
- Gross Profit
- -79.50M
- Operating Income
- -79.50M
- Pretax Income
- -145.91M
- Net Income
- -145.91M
- EBITDA
- -77.18M
- Earnings Per Share (EPS)
- -0.42
Cash Flow
In the last 12 months, operating cash flow was -76.15M and capital expenditures 0, giving a free cash flow of -76.15M billion.
- Operating Cash Flow
- -76.15M
- Free Cash Flow
- -76.15M
- Free Cash Flow per Share
- -0.11
Dividends & Yields
Immunovia AB pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -418.20%
- Earnings Yield
- -371.39%
Stock Price Statistics
- Beta
- 109.46
- 52-Week Price Change
- -65.52%
- 50-Day Moving Average
- 0.01
- 200-Day Moving Average
- 0.01
- Relative Strength Index (RSI)
- 31.41
- Average Volume (3m)
- ―
Important Dates
Immunovia AB upcoming earnings date is Feb 11, 2027, Before Open (Not Confirmed).
- Last Earnings Date
- Nov 02, 2026
- Next Earnings Date
- Feb 11, 2027
- Ex-Dividend Date
- ―
Financial Position
Immunovia AB as a current ratio of 5.12, with Debt / Equity ratio of 1.32%
- Current Ratio
- 5.12
- Quick Ratio
- 5.12
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.99
- Interest Coverage Ratio
- -1.20
Taxes
In the past 12 months, Immunovia AB has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Immunovia AB EV to EBITDA ratio is -0.02, with an EV/FCF ratio of -0.02.
- EV to Sales
- 0.78
- EV to EBITDA
- -0.02
- EV to Free Cash Flow
- -0.02
- EV to Operating Cash Flow
- -0.02
Balance Sheet
Immunovia AB has EUR 19.62M in cash and marketable securities with EUR 2.93M in debt, giving a net cash position of EUR 16.69M billion.
- Cash & Marketable Securities
- EUR 19.62M
- Total Debt
- EUR 2.93M
- Net Cash
- EUR 16.69M
- Net Cash Per Share
- EUR 0.01
- Tangible Book Value Per Share
- EUR 0.00
Margins
Gross margin is -1722.28%, with operating margin of -3857.63%, and net profit margin of -3903.48%.
- Gross Margin
- -1722.28%
- Operating Margin
- -3857.63%
- Pretax Margin
- -3903.48%
- Net Profit Margin
- -3903.48%
- EBITDA Margin
- -3710.04%
- EBIT Margin
- -3815.88%
Analyst Forecast
The average price target for Immunovia AB is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 157.39%
- EPS Growth Forecast
- 65.73%
